Logo image of COV.PA

COVIVIO (COV.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:COV - FR0000064578 - REIT

55.7 EUR
+0.05 (+0.09%)
Last: 11/28/2025, 7:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to COV. COV was compared to 42 industry peers in the Diversified REITs industry. While COV is still in line with the averages on profitability rating, there are concerns on its financial health. COV is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

COV had positive earnings in the past year.
COV had a positive operating cash flow in the past year.
Of the past 5 years COV 4 years were profitable.
Each year in the past 5 years COV had a positive operating cash flow.
COV.PA Yearly Net Income VS EBIT VS OCF VS FCFCOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B -1B

1.2 Ratios

The Return On Assets of COV (1.63%) is comparable to the rest of the industry.
COV has a Return On Equity (5.08%) which is in line with its industry peers.
Looking at the Return On Invested Capital, with a value of 3.21%, COV is in line with its industry, outperforming 50.00% of the companies in the same industry.
COV had an Average Return On Invested Capital over the past 3 years of 2.97%. This is in line with the industry average of 3.52%.
The 3 year average ROIC (2.97%) for COV is below the current ROIC(3.21%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROIC 3.21%
ROA(3y)-1.05%
ROA(5y)0.29%
ROE(3y)-3.48%
ROE(5y)0.76%
ROIC(3y)2.97%
ROIC(5y)2.68%
COV.PA Yearly ROA, ROE, ROICCOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10

1.3 Margins

COV has a Profit Margin (30.46%) which is comparable to the rest of the industry.
COV's Profit Margin has declined in the last couple of years.
COV's Operating Margin of 57.81% is on the low side compared to the rest of the industry. COV is outperformed by 64.29% of its industry peers.
COV's Operating Margin has been stable in the last couple of years.
COV's Gross Margin of 74.42% is in line compared to the rest of the industry. COV outperforms 57.14% of its industry peers.
COV's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 57.81%
PM (TTM) 30.46%
GM 74.42%
OM growth 3Y-1.46%
OM growth 5Y-1.11%
PM growth 3Y-61.53%
PM growth 5Y-38.78%
GM growth 3Y-2.18%
GM growth 5Y-0.89%
COV.PA Yearly Profit, Operating, Gross MarginsCOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), COV is destroying value.
COV has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, COV has more shares outstanding
The debt/assets ratio for COV has been reduced compared to a year ago.
COV.PA Yearly Shares OutstandingCOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COV.PA Yearly Total Debt VS Total AssetsCOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

COV has an Altman-Z score of 0.53. This is a bad value and indicates that COV is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.53, COV is doing worse than 71.43% of the companies in the same industry.
COV has a debt to FCF ratio of 28.44. This is a negative value and a sign of low solvency as COV would need 28.44 years to pay back of all of its debts.
The Debt to FCF ratio of COV (28.44) is worse than 71.43% of its industry peers.
COV has a Debt/Equity ratio of 1.07. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.07, COV is doing worse than 78.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.44
Altman-Z 0.53
ROIC/WACC0.55
WACC5.79%
COV.PA Yearly LT Debt VS Equity VS FCFCOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

A Current Ratio of 0.76 indicates that COV may have some problems paying its short term obligations.
COV has a Current ratio of 0.76. This is in the better half of the industry: COV outperforms 66.67% of its industry peers.
COV has a Quick Ratio of 0.76. This is a bad value and indicates that COV is not financially healthy enough and could expect problems in meeting its short term obligations.
With a decent Quick ratio value of 0.69, COV is doing good in the industry, outperforming 64.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.69
COV.PA Yearly Current Assets VS Current LiabilitesCOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.98% over the past year.
The Earnings Per Share has been decreasing by -3.39% on average over the past years.
The Revenue has grown by 27.96% in the past year. This is a very strong growth!
The Revenue has been growing slightly by 1.17% on average over the past years.
EPS 1Y (TTM)5.98%
EPS 3Y0.91%
EPS 5Y-3.39%
EPS Q2Q%6.25%
Revenue 1Y (TTM)27.96%
Revenue growth 3Y9.01%
Revenue growth 5Y1.17%
Sales Q2Q%-30.61%

3.2 Future

The Earnings Per Share is expected to grow by 3.36% on average over the next years.
COV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.88% yearly.
EPS Next Y5.08%
EPS Next 2Y3.25%
EPS Next 3Y3.36%
EPS Next 5YN/A
Revenue Next Year-1.08%
Revenue Next 2Y1.65%
Revenue Next 3Y2.88%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
COV.PA Yearly Revenue VS EstimatesCOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
COV.PA Yearly EPS VS EstimatesCOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 12.08, COV is valued correctly.
Based on the Price/Earnings ratio, COV is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of COV to the average of the S&P500 Index (26.31), we can say COV is valued rather cheaply.
COV is valuated reasonably with a Price/Forward Earnings ratio of 11.69.
COV's Price/Forward Earnings is on the same level as the industry average.
COV's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.59.
Industry RankSector Rank
PE 12.08
Fwd PE 11.69
COV.PA Price Earnings VS Forward Price EarningsCOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, COV is valued a bit cheaper than the industry average as 61.90% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of COV indicates a slightly more expensive valuation: COV is more expensive than 61.90% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 15.81
EV/EBITDA 17
COV.PA Per share dataCOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)2.38
PEG (5Y)N/A
EPS Next 2Y3.25%
EPS Next 3Y3.36%

4

5. Dividend

5.1 Amount

COV has a Yearly Dividend Yield of 6.29%, which is a nice return.
COV's Dividend Yield is a higher than the industry average which is at 5.87.
Compared to an average S&P500 Dividend Yield of 2.40, COV pays a better dividend.
Industry RankSector Rank
Dividend Yield 6.29%

5.2 History

The dividend of COV decreases each year by -1.54%.
Dividend Growth(5Y)-1.54%
Div Incr Years2
Div Non Decr Years2
COV.PA Yearly Dividends per shareCOV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

5.3 Sustainability

92.95% of the earnings are spent on dividend by COV. This is not a sustainable payout ratio.
DP92.95%
EPS Next 2Y3.25%
EPS Next 3Y3.36%
COV.PA Yearly Income VS Free CF VS DividendCOV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B
COV.PA Dividend Payout.COV.PA Dividend Payout, showing the Payout Ratio.COV.PA Dividend Payout.PayoutRetained Earnings

COVIVIO

EPA:COV (11/28/2025, 7:00:00 PM)

55.7

+0.05 (+0.09%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)07-21 2025-07-21/bmo
Earnings (Next)02-18 2026-02-18/amc
Inst Owners41.52%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap6.22B
Revenue(TTM)1.37B
Net Income(TTM)417.86M
Analysts81.25
Price Target64.42 (15.66%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.29%
Yearly Dividend0.72
Dividend Growth(5Y)-1.54%
DP92.95%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.26%
PT rev (3m)0.03%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-2.85%
Revenue NY rev (3m)-1.19%
Valuation
Industry RankSector Rank
PE 12.08
Fwd PE 11.69
P/S 4.53
P/FCF 15.81
P/OCF 6.19
P/B 0.76
P/tB 0.79
EV/EBITDA 17
EPS(TTM)4.61
EY8.28%
EPS(NY)4.77
Fwd EY8.55%
FCF(TTM)3.52
FCFY6.33%
OCF(TTM)8.99
OCFY16.15%
SpS12.29
BVpS73.66
TBVpS70.57
PEG (NY)2.38
PEG (5Y)N/A
Graham Number87.41
Profitability
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROCE 3.59%
ROIC 3.21%
ROICexc 3.42%
ROICexgc 3.48%
OM 57.81%
PM (TTM) 30.46%
GM 74.42%
FCFM 28.68%
ROA(3y)-1.05%
ROA(5y)0.29%
ROE(3y)-3.48%
ROE(5y)0.76%
ROIC(3y)2.97%
ROIC(5y)2.68%
ROICexc(3y)3.08%
ROICexc(5y)2.79%
ROICexgc(3y)3.11%
ROICexgc(5y)2.81%
ROCE(3y)3.32%
ROCE(5y)3%
ROICexgc growth 3Y12.16%
ROICexgc growth 5Y0.31%
ROICexc growth 3Y11.77%
ROICexc growth 5Y0.14%
OM growth 3Y-1.46%
OM growth 5Y-1.11%
PM growth 3Y-61.53%
PM growth 5Y-38.78%
GM growth 3Y-2.18%
GM growth 5Y-0.89%
F-Score7
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.44
Debt/EBITDA 9.39
Cap/Depr 417.19%
Cap/Sales 44.51%
Interest Coverage 250
Cash Conversion 106.87%
Profit Quality 94.14%
Current Ratio 0.76
Quick Ratio 0.69
Altman-Z 0.53
F-Score7
WACC5.79%
ROIC/WACC0.55
Cap/Depr(3y)709.28%
Cap/Depr(5y)708.5%
Cap/Sales(3y)50.08%
Cap/Sales(5y)56.76%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.98%
EPS 3Y0.91%
EPS 5Y-3.39%
EPS Q2Q%6.25%
EPS Next Y5.08%
EPS Next 2Y3.25%
EPS Next 3Y3.36%
EPS Next 5YN/A
Revenue 1Y (TTM)27.96%
Revenue growth 3Y9.01%
Revenue growth 5Y1.17%
Sales Q2Q%-30.61%
Revenue Next Year-1.08%
Revenue Next 2Y1.65%
Revenue Next 3Y2.88%
Revenue Next 5YN/A
EBIT growth 1Y-0.73%
EBIT growth 3Y7.42%
EBIT growth 5Y0.05%
EBIT Next Year12.82%
EBIT Next 3Y8.12%
EBIT Next 5Y8.08%
FCF growth 1Y42.08%
FCF growth 3YN/A
FCF growth 5Y31.13%
OCF growth 1Y30.56%
OCF growth 3Y12.5%
OCF growth 5Y4.86%

COVIVIO / COV.PA FAQ

Can you provide the ChartMill fundamental rating for COVIVIO?

ChartMill assigns a fundamental rating of 3 / 10 to COV.PA.


What is the valuation status of COVIVIO (COV.PA) stock?

ChartMill assigns a valuation rating of 4 / 10 to COVIVIO (COV.PA). This can be considered as Fairly Valued.


Can you provide the profitability details for COVIVIO?

COVIVIO (COV.PA) has a profitability rating of 4 / 10.


What is the earnings growth outlook for COVIVIO?

The Earnings per Share (EPS) of COVIVIO (COV.PA) is expected to grow by 5.08% in the next year.


Can you provide the dividend sustainability for COV stock?

The dividend rating of COVIVIO (COV.PA) is 4 / 10 and the dividend payout ratio is 92.95%.